Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for ENANTA PHARMACEUTICALS INC Common Stock, par value $0.01 per share (ENTA).
- Disclosed ownership: 6.8%.
- Date of event: 31 Dec 2025.
Deep Track Capital, LP - 31 Dec 2025 SCHEDULE 13G/A Report for ENANTA PHARMACEUTICALS INC Common Stock, par value $0.01 per share (ENTA)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- ENTA
- Shares outstanding
- 28,862,345 shares
- Disclosed Ownership
- 1,956,867 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 08:43:46 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 09 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 6.8% ownership in ENANTA PHARMACEUTICALS INC Common Stock, par value $0.01 per share (ENTA) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 09 Oct 2025.
- Current filing was accepted on 13 Feb 2026, 08:43.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 6.8% | 1,956,867 | 0 | 1,956,867 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 6.8% | 1,956,867 | 0 | 1,956,867 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 6.8% | 1,956,867 | 0 | 1,956,867 | /s/ David Kroin | David Kroin |